Equities Analysts Set Expectations for MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($1.91) per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same period in the previous year, the business posted ($0.18) EPS.

A number of other equities analysts have also weighed in on the company. Wedbush reissued an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th. Finally, The Goldman Sachs Group upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $62.00 to $82.00 in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Buy” and a consensus target price of $84.29.

MoonLake Immunotherapeutics Price Performance

MLTX stock opened at $45.70 on Thursday. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $64.98. The firm has a market capitalization of $2.92 billion, a PE ratio of -35.43 and a beta of 1.31. The business has a 50 day simple moving average of $51.06 and a 200-day simple moving average of $49.08.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. US Bancorp DE acquired a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at about $44,000. Quarry LP boosted its position in shares of MoonLake Immunotherapeutics by 172.7% during the 2nd quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $132,000 after purchasing an additional 1,900 shares during the period. Barclays PLC increased its holdings in MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after purchasing an additional 5,229 shares during the last quarter. Handelsbanken Fonder AB raised its position in MoonLake Immunotherapeutics by 26.2% in the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new position in MoonLake Immunotherapeutics during the third quarter worth $706,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.